18-45038613-G-C
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2
The NM_015559.3(SETBP1):āc.4129G>Cā(p.Val1377Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0128 in 1,614,182 control chromosomes in the GnomAD database, including 162 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Benign (ā ā ). Another nucleotide change resulting in same amino acid change has been previously reported as Likely benignin UniProt. Synonymous variant affecting the same amino acid position (i.e. V1377V) has been classified as Benign.
Frequency
Consequence
NM_015559.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -20 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SETBP1 | NM_015559.3 | c.4129G>C | p.Val1377Leu | missense_variant | 5/6 | ENST00000649279.2 | NP_056374.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SETBP1 | ENST00000649279.2 | c.4129G>C | p.Val1377Leu | missense_variant | 5/6 | NM_015559.3 | ENSP00000497406 | P2 |
Frequencies
GnomAD3 genomes AF: 0.00897 AC: 1365AN: 152218Hom.: 13 Cov.: 32
GnomAD3 exomes AF: 0.00812 AC: 2041AN: 251392Hom.: 12 AF XY: 0.00837 AC XY: 1137AN XY: 135854
GnomAD4 exome AF: 0.0132 AC: 19329AN: 1461846Hom.: 149 Cov.: 32 AF XY: 0.0131 AC XY: 9513AN XY: 727230
GnomAD4 genome AF: 0.00895 AC: 1364AN: 152336Hom.: 13 Cov.: 32 AF XY: 0.00812 AC XY: 605AN XY: 74492
ClinVar
Submissions by phenotype
not provided Benign:5
Benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jul 01, 2024 | SETBP1: BP4, BS1, BS2 - |
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Likely benign, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The SETBP1 p.Val1377Leu variant was not identified in the literature but was identified in dbSNP (ID: rs77518617), ClinVar (classified as benign by Genetic Services Laboratory, University of Chicago and likely benign by Illumina) and LOVD 3.0 (classified as likely benign and benign). The variant was identified in control databases in 2336 of 282752 chromosomes (16 homozygous) at a frequency of 0.008262 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database March 6, 2019, v2.1.1). The variant was observed in the following populations: European (non-Finnish) in 1719 of 129086 chromosomes (freq: 0.01332), Ashkenazi Jewish in 137 of 10366 chromosomes (freq: 0.01322), Other in 63 of 7228 chromosomes (freq: 0.008716), Latino in 213 of 35422 chromosomes (freq: 0.006013), African in 73 of 24968 chromosomes (freq: 0.002924), South Asian in 72 of 30614 chromosomes (freq: 0.002352) and European (Finnish) in 59 of 25116 chromosomes (freq: 0.002349), but was not observed in the East Asian population. The p.Val1377 residue is conserved across mammals and other organisms however four out of five computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein; this information is not predictive enough to rule out pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign. - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | Mar 03, 2015 | This variant is associated with the following publications: (PMID: 31681433) - |
not specified Benign:1
Benign, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Feb 08, 2013 | - - |
Schinzel-Giedion syndrome Benign:1
Benign, criteria provided, single submitter | clinical testing | KCCC/NGS Laboratory, Kuwait Cancer Control Center | Jul 07, 2023 | - - |
SETBP1-related disorder Benign:1
Benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Dec 07, 2020 | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at